Showing 7261-7270 of 8194 results for "".
- MKTP Surgery Shows Long-Term Benefit for Restoring Skin Pigmentation in Vitiligohttps://practicaldermatology.com/news/mktp-surgery-shows-long-term-benefit-for-restoring-skin-pigmentation-in-vitiligo/2458103/Melanocyte-keratinocyte transplantation (MKTP) provides long-term benefits for restoring skin pigmentation caused by vitiligo, report researchers from Henry Ford Hospital in Detroit. “MKTP works and it lasts a long time,” says Iltefat Hamzavi, M.D., a Henry Ford dermatologist
- Valeant Launches Siliq Injection for Psoriasishttps://practicaldermatology.com/news/valeant-launches-siliq-injection-for-psoriasis/2458107/Valeant Pharmaceuticals International, Inc. launched Siliq (brodalumab) Injection during the Summer American Academy of Dermatology (AAD) meeting taking place in New York from July 27-30, 2017. Siliq, a
- Boehringer Ingelheim Begins Interchangeability Study Between Adalimumab Biosim and Humirahttps://practicaldermatology.com/news/boehringer-ingelheim-begins-interchangeability-study-between-adalimumab-biosim-and-humira/2458106/The first patient has been enrolled into the VOLTAIRE-X interchangeability study, which seeks to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40 mg/0.8 ml. This is the first study in the U.S. to investigate an interchange
- Study IDs Risk Factors for Melanoma in Kidney Transplant Recipientshttps://practicaldermatology.com/news/study-ids-risk-factors-for-melanoma-in-kidney-transplant-recipients/2458108/Kidney transplant patients appear to be at a greater risk of developing melanoma than the general population and risk factors include being older, male and white, findings that corroborate results demonstrated in other studies, according to a new article published by
- Simulation Techniques Help Medical Students Empathize with Melanoma Patientshttps://practicaldermatology.com/news/simulation-techniques-help-medical-students-empathize-with-melanoma-patients/2458110/Simulation techniques can allow doctors to experience what it feels like to be a melanoma patient. The study, which is led by Queen’s University in Belfast collaboration with researchers from the University of Huddersfield and University College Dublin, appears in the
- Patent Challenge Filed for Generic Version Of Soolantra Creamhttps://practicaldermatology.com/news/patent-challenge-filed-for-generic-version-of-soolantra-cream/2458120/Perrigo Company plc's subsidiary has filed a Paragraph IV Abbreviated New Drug Application with the FDA for a generic version of Soolantra® (ivermectin) cream, 1%. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a
- Tomatoes May Slash Skin Cancer Riskhttps://practicaldermatology.com/news/tomatoes-may-slash-skin-cancer-risk/2458122/Daily tomato consumption may cut skin cancer risk in half, according to a new study in mice. The Ohio State University researchers report their findings online in the journal
- Samsung Biologics to Manufacture Sun Pharma's Tildrakizumab for Psoriasishttps://practicaldermatology.com/news/samsung-biologics-to-manufacture-sun-pharmas-tildrakizumab-for-psoriasis/2458130/Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis. The investigational IL-23p19 inhibitor drug is currently under review by the US Food & Drug Admi
- Array BioPharma Submits NDAs for Binimetinib and Encorafenib in Advanced Melanomahttps://practicaldermatology.com/news/array-biopharma-submits-ndas-for-binimetinib-and-encorafenib-in-advanced-melanoma/2458131/Array BioPharma submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with&nbs
- Aclaris Initiates Phase 2b Trials of A-101 for Topical Treatment of Common Wartshttps://practicaldermatology.com/news/aclaris-initiates-phase-2b-trials-of-a-101-for-topical-treatment-of-common-warts/2458135/Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription